TO EVALUATE AND COMPARE THE SAFETY AND EFFICACY OF CYSTEAMINE 5% & KOJIC ACID 2% IN MELASMA. - NI

GLENMARK PHARMACEUTICALS LTD.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1.Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.
•2.Having refused to give her assent by not signing the consent form.
•3.Taking part in another study liable to interfere with this study.
•4.Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
•5.Having progressive asthma.
•6.Being epileptic.
•7.Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
•8.Having cutaneous hypersensitivity
•9.Having a diagnosed or highly probable allergy to one or several compounds of cosmetic products.
•10.Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
•11.Having consumed caffeine-based products (coffee, cola, tea …), alcohol, highly spiced foods and/or smoked in the two hours preceding the measurements.
•12.Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.
•13.Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit
•14.Having applied a cosmetic product (included make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted)

发起方

GLENMARK PHARMACEUTICALS LTD.